1,731 results on '"Brenner, Malcolm K."'
Search Results
202. Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4 + T cells
203. Reduced Autoimmune Cytopenias after Cord Blood Transplant in Pediatric Patients with Nonmalignant Disease Conditioned without Serotherapy
204. Excellent Engraftment with Reduced Treatment Related Mortality for Young Pediatric Patients Using Umbilical Cord Blood Transplantation (UCBT) Conditioned without Serotherapy
205. CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity
206. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells
207. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis
208. An inducible caspase 9 safety switch for T-cell therapy
209. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes
210. Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas
211. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia
212. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells
213. Retinoblastoma Treatment
214. Genetic Modification of T Lymphocytes for Adoptive Immunotherapy
215. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications
216. An in vivo propagated human acute myeloid leukemia expressing ABCA3
217. TRANSPLANTATION AND VIRUS INFECTIONS
218. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
219. Complement-Fixing CD45 Monoclonal Antibodies to Facilitate Stem Cell Transplantation in Mouse and Man
220. Chapter 100 - T-Cell Therapy of Hematologic Diseases
221. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
222. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells
223. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses
224. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect
225. Anti-CD45–mediated cytoreduction to facilitate allogeneic stem cell transplantation
226. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma
227. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity
228. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy
229. 281 - Safety and Tolerability of Administering Leukemia-Specific Donor T Cells (mLSTs) after Allogeneic Transplant to Pediatric Patients with AML/MDS
230. 245 - Long Term Follow up for the Development of Subsequent Malignancies in Patients Treated with Genetically Modified Immune Effectors
231. 129 - Phase I Trial of GD2.CAR T Cells Combined with a Novel Interleukin-7 Signal Modulator
232. 26 - Evaluating the Safety and Clinical Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma
233. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells
234. Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia
235. Single Cell RNA Sequencing Identifies Transcriptional Programs That Enhance Anti-Tumor Function of Transgenic CD4+ T Cells Redirected with TCR and CD8αβ
236. Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies
237. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
238. Rejection-resistant off-the-shelf T cells for adoptive cell therapy
239. Adoptive Cell Therapy: ACT-Up or ACT-Out?
240. Chimeric Antigen Receptors for T-Cell Malignancies
241. CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)
242. Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor-Associated Antigens
243. Excellent Outcomes for Pediatric Non-Malignant Diseases Using Umbilical Cord Blood Transplantation (UCBT) Conditioned without Serotherapy in the Absence of a Matched Related Donor
244. Targeting Lymphomas Using Non-Engineered, Multi-Antigen-Specific T Cells
245. Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma
246. Administering Leukemia-Directed Donor Lymphocytes to Patients with AML or MDS to Prevent or Treat Post-Allogeneic HSCT Relapse
247. Optimizing C-Type Lectin-like Molecule 1 (CLL-1) Directed CAR T Cell Therapy of Acute Myeloid Leukemia
248. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
249. Autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for the treatment of persistent active EBV infection
250. Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40− plasmacytoma cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.